Overview

Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants

Status:
Not yet recruiting

Trial end date:
2023-10-31

Target enrollment:

Participant gender:

Summary

The primary purpose of the study is to evaluate the effect of increased metabolizing enzyme (cytochrome P450 [CYP] 3A4) due to carbamazepine, a strong CYP3A4 inducer, on the pharmacokinetics (PK) of darigabat in healthy adult participants.

Phase:

Phase 1

Details

Lead Sponsor:

Cerevel Therapeutics, LLC

Treatments:

Carbamazepine